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Retinoic acid exerts a variety of effects on gene transcription that regulate growth, differentiation, and inﬂammation
in normal and neoplastic skin cells. Because there is a lack of information regarding the inﬂuence of metabolic
transformation of retinoids on their pharmacologic effects in skin, we have analyzed the functional activity of all-
trans-, 9-cis-, and 13-cis-retinoic acid and their 4-oxo-metabolites in normal human epidermal keratinocytes
(NHEKs) and dermal ﬁbroblasts using gene and protein expression proﬁling techniques, including cDNA microar-
rays, two-dimensional gel electrophoresis, and MALDI-MS. It was previously thought that the 4-oxo-metabolites of
RA are inert catabolic end-products but our results indicate instead that they display strong and isomer-specific
transcriptional regulatory activity in both NHEKs and dermal ﬁbroblasts. Microarray and proteomic analyses iden-
tiﬁed a number of novel genes/gene products that are inﬂuenced by RA treatment of NHEKs or ﬁbroblasts, in-
cluding genes for enzymes catalyzing biotransformation of retinoids, corticosteroids, and antioxidants and
structural and transport proteins known to be essential for homeostasis. Our results expand current knowledge
regarding retinoic acid action within skin cells and the target tissue/cell regulatory systems that are important for
modulating the physiological and pharmacological effects of this important class of dermatological drugs.
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Retinoids (vitamin A and its analogs) are crucial for main-
taining the homeostasis of cells and tissues including pro-
liferation and differentiation (Gudas et al, 1994). Aside from
vision, the physiologic activity of retinoids is thought to be
mediated primarily by the all-trans- and 9-cis-retinoic acid
(RA) isomers that regulate transcription following binding
to their cognate ligand-dependent transcription factors,
the RA receptors (RAR), and retinoid X receptors (RXR)
(Chambon, 1994, 1996; Mangelsdorf et al, 1994, 1995; Ross
et al, 2000; Chawla et al, 2001; Clagett-Dame and DeLuca,
2002). Several hundred genes may be regulated by all-
trans- and/or 9-cis-RA (Balmer and Blomhoff, 2002).
The skin is a stratified squamous epithelium and a major
site of RA action (Peck and DiGiovanna, 1994; Roos et al,
1998; Blaner, 2001; Zouboulis, 2001). Vitamin A deficiency
is known to result in squamous metaplasia of a variety of
epithelia that is often associated with increased cell prolif-
eration and hyperkeratosis in the skin (Peck et al, 1949).
From studies of vitamin A-deficient animals and observation
of vitamin A-deficient human infants, it was suggested that
vitamin A deficiency gives rise to follicular keratoses re-
sembling Darier’s disease or pityriasis rubra pilaris (Peck
and DiGiovanna, 1994). Initial attention focused on the
naturally occurring all-trans- and 13-cis-RA isomers as
potentially effective for treating skin disease (Peck and
DiGiovanna, 1994; Roos et al, 1998; Shroot et al, 1999;
Blaner, 2001; Zouboulis, 2001). More recently, a number of
synthetic RA analogs with enhanced therapeutic efficacy
have been developed (Peck and DiGiovanna, 1994; Roos
et al, 1998; Shroot et al, 1999; Blaner, 2001; Zouboulis,
2001). It is important to emphasize that the skin has both a
physiologic requirement for RA and responds to pharmaco-
logic doses of natural or synthetic retinoids that are effective
for treating patients with skin disease (Peck et al, 1949).
Since human skin cells express both RAR and RXR (Peck
and DiGiovanna, 1994; Roos et al, 1998; Shroot et al, 1999;
Zouboulis, 2001), it is reasonable to assume that retinoid
effects in skin are mediated by retinoid-dependent tran-
scription factors. Interestingly, the binding affinity of 13-cis-
RA for the RAR and RXR and its activity in transactiva-
tion assays is substantially less than that for either all-trans-
or 9-cis-RA (Mangelsdorf et al, 1992, 1994; Beard and
Chandraratna, 1999). Yet, it is well established that 13-cis-1Both authors contributed equally to this work.
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RA exerts pharmacological effects that cannot be recapit-
ulated by either all-trans- or 9-cis-RA, raising questions re-
garding the molecular basis underlying the remarkable
efficacy of 13-cis-RA efficacy in acne vulgaris (Peck and
DiGiovanna, 1994; Roos et al, 1998; Shroot et al, 1999;
Blaner, 2001; Zouboulis, 2001). One possibility is that the
superior clinical efficacy of 13-cis-RA in acne as compared
with all-trans- or 9-cis-RA could relate to unique pharmaco-
kinetic properties of this isomer (Peck and DiGiovanna,
1994; Blaner, 2001). In addition, the drug may act directly on
proteins in skin cells by covalent and non-covalent binding.
There is a substantial literature indicating that RA can co-
valently bind to proteins, thereby altering cell signaling
pathways (Takahashi et al, 1991a, b; Takahashi and Breit-
man, 1992; Myhre et al, 1996; Hoyos et al, 2000; Ra-
dominska-Pandya et al, 2000; Imam et al, 2001; Korichneva
et al, 2003). Another possibility is that the effects of 13-cis-
RA in acne are indirect, acting for instance via competitive
inhibition of enzymes involved in the bioactivation of an-
drogenes (Karlsson et al, 2003). Alternatively, it is possible
that one or more metabolites formed from 13-cis-RA could
display transcriptional regulatory activity. To assess these
possibilities, we have studied the metabolism and actions of
13-cis-RA in primary cultures of normal human skin cells. To
conduct these studies, we used gene arrays and two-di-
mensional (2D) sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) separations of proteins cou-
pled with matrix-assisted laser desorption ionization-mass
spectrometry (MALDI-MS) identification of the proteins to
explore various modes of action of all-trans-, 13-cis-, 9-cis-
RA, and their oxo-metabolites in these cells.
Results
cDNA microarray analysis of the effects of RA and its
oxo-metabolites on normal human epidermal keratin-
ocytes (NHEK) and dermal ﬁbroblast gene expres-
sion To explore the mechanism whereby all-trans-, 13-
cis-, and 9-cis-RA isomers and their 4-oxo-metabolites
might differentially affect gene expression when added to
cultured NHEK and fibroblasts, each of the RA isomers and
4-oxo-RA species was added to primary cultures of NHEK
or fibroblasts for 24 h, and analysis of differential gene ex-
pression was performed using DNA-Chip technology (Fig 1).
We analyzed the expression of sequence-validated cDNA
arrayed on PIQOR Skin Microarray using ImaGene software
version 4.1 (Table I and Tables S1 and S2). There were
substantial differential effects of the RA isomers on gene
expression. Incubation of NHEK with 106 M of each RA
isomer for 24 h led to upregulation of keratins 7, 15, and 19
as well as interleukin-1 (IL-1)b, tissue-type plasminogen
activator, and others (Table I and Table S1). We detected a
significant downregulation of keratins 1, 10, 14, and 17 as
well as matrix metalloproteinase (MMP)-10, vascular end-
othelial growth factor (VEGF)-C, thrombospondin-1, plasm-
inogen activator inhibitor-2, cyclooxygenase-2, psoriasis-
associated fatty acid-binding protein (PA-FABP), and
filaggrin and other genes by all-trans-, 13-cis-, and 9-cis-
RA (Table I and Table S1). Expression of S100 calcium-
binding protein A8 was upregulated by 13-cis- but down-
regulated by and all-trans- and 9-cis-RA.
Interestingly, the 4-oxo-metabolites had very similar ef-
fects on expression profiles as those observed for their
parent compounds (Table I and Table S1). The 4-oxo-met-
abolites of RA, especially 4-oxo-13-cis-RA, are generally
thought to be inert catabolic end-products that are destined
for elimination. As evidenced in Table I and Table S1, how-
ever, these metabolites, which cannot be converted back to
RA, have substantial transcriptional activity. Incubation of
NHEK with these substances for 3 h revealed minor chang-
es in gene expression profiles (Table S2).
Incubation of dermal ﬁbroblasts with the RA isomers for
24 h revealed more substantial changes than those ob-
served in NHEK, including downregulation of p-450-
dependent enzymes involved in xenobiotic/endogenous
biotransformation, including cytochrome P450 (CYP)2D,
CYP3A7, CYP4A1, corticosteroid 11b-dehydrogenase,
prostaglandin-endoperoxide synthase 1, dual specificity
phosphatase 11, glutathione S transferase M1, and trans-
port proteins like solute carrier family 16 (SLC16A1) (Table
S3). Similar effects were seen for most of the RA isomers
and their 4-oxo-RA isomers. The RA and their 4-oxo met-
abolites downregulated fibroblast Fas-activated serine/
threonine kinase, growth factor receptor-bound protein 7,
epidermal growth factor receptor, collagen types VI and
XVII, as well as protease inhibitor 8 and 9 (4-oxo-) 13-cis-,
(4-oxo-) all-trans-, and (4-oxo-)-9-cis-RA. Expression of an-
nexin A1, annexin A5, thymosin b4, ribosomal protein S13,
apolipoprotein D, and insulin-like growth factor-binding pro-
tein 3 was upregulated in skin fibroblasts by 4-oxo-13-cis-,
all-trans-, and 4-oxo-all-trans-RA but not by 9-cis-, 4-oxo-
9-cis-, and 13-cis-RA.
Real-time PCR (RT-PCR) conﬁrmation of gene array
data RT-PCR analysis in NHEK incubated with 106 M
retinoids using specific primers for the detection of cytok-
eratins 1, 10, 13, and 19 confirmed strong upregulation of
cytokeratins 13 and 19 by 13-cis-RA but a weaker upreg-
ulation by all-trans-, 9-cis-, 4-oxo-13-cis-, 4-oxo-all-trans-,
and 4-oxo-9-cis-RA (Fig 2b and d). In accordance with the
cDNA microarray data, we also observed downregulation of
cytokeratins 1 and 10 and MMP-3 by all-trans-, 9-cis-, and
13-cis-RA and their 4-oxo-metabolites (Fig 2a, c, and e).
Since there were no available cDNA probes specific for the
detection of lamin B1 on the microarrays used in this
project, our 2D-gel data were also directly confirmed by
real-time PCR (Fig 3f). Only a weak upregulation of lamin B1
mRNA expression in NHEK occurred after incubation with
each of the six different retinoids, especially after incubation
with 13-cis- or 4-oxo-13-cis-RA. Real-time PCR analyses of
NHEK incubated with 107 M concentration of the retinoids
revealed similar effects (Table S4). When cells were in-
cubated with these substances at a lower concentration
(108 M), upregulation of keratins 13 and 19 and downreg-
ulation of MMP-3 were still detectable, whereas expression
of keratins 1, 10, and lamin B1 was not significantly reg-
ulated (Table S4).
Immunoﬂuorescence analysis of the effects of 13-cis-
and 4-oxo-13-cis-RA on NHEK expression of cytokera-
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tins 7 and 19 To determine whether the changes in mRNA
levels detected following treatment with 10–6 M 13-cis-, all-
trans-, 9-cis-, 4-oxo-13-cis-, 4-oxo-all-trans-, or 4-oxo-9-
cis-RA influence protein expression, we analyzed NHEK
monolayers using specific antibodies and confirmed up-
regulation of cytokeratins 7 (Fig 3a) and 19 (Fig 3b) expres-
sion in response to all retinoids analyzed. As can be seen
from this figure, both of these proteins are expressed at
higher levels in treated NHEK, indicating that protein ex-
pression as well as mRNA levels for these two proteins are
upregulated following addition of 13-cis-, all-trans-, 9-cis-,
4-oxo-13-cis-, 4-oxo-all-trans-, or 4-oxo-9-cis-RA.
NHEK protein separation by 2D PAGE We further as-
sessed the effects of different RA isomers on protein ex-
pression patterns in these cells. We isolated proteins from
vehicle-, all-trans- and 13-cis-RA-treated NHEK and sepa-
rated them on 2D SDS-PAGE (2D PAGE) gels. Examples of
silver-stained 2D PAGE gels for all-trans-RA-, 13-cis-RA-,
and vehicle-treated NHEK are shown in Figure S1. Since
each of the duplicate NHEK cell samples was analyzed by
two independent 2D PAGE runs, it was possible to assess
the variable intensity of the protein spots for each gel and
each treatment. For this analysis, the integrated areas (pro-
tein spot percentages) for 371 protein spots on each gel for
each of the thre treatments (vehicle, all-trans-, and 13-cis-
RA) were included. Statistical analysis indicated that the
cube root transformation of the data gave the best linear
relationship between the magnitude of the mean spot per-
centage and the standard deviation of these measures. This
analysis of integrated spot areas also indicated that both the
cell treatments and the 2D electrophoresis contributed to the
measured variability. Most of the variability arose, however,
from the running of the 2D gels, the staining of the gels, and
the subsequent densitometric measures carried out on the
stained gels. From this analysis, it was possible to predict
statistically which differences in spot intensities were because
of treatment with all-trans-, 13-cis-RA, or both. We thus iden-
tified cellular proteins whose apparent concentrations within
NHEK varied substantially (po0.01) after treatment with all-
trans- and/or 13-cis-RA from vehicle-treated cells.
Overall, we identified 34 protein spots in NHEK whose
intensities increased or decreased in response to treatment
with either all-trans- and/or 13-cis-RA. The intensities of four
of the protein spots (i.e. the cellular concentration of the pro-
tein) changed by more than 3-fold (three increased and one
decreased). The magnitude of change in the concentrations
for other protein spots was less substantial; nonetheless, for
34 of the remaining protein spots, statistically significant
changes in spot intensities were observed following treat-
ment with all-trans- and/or 13-cis-RA. Ten NHEK protein
concentrations responded solely to 13-cis-RA treatment and
not to all-trans-RA (five increased and five decreased),
whereas six NHEK protein concentrations responded solely
to all-trans-RA treatment and not to 13-cis-RA (all de-
creased). For 18 protein spots, NHEK protein concentrations
responded similarly to both all-trans- and 13-cis-RA.
We conducted a second study using 26 h treatment with
all-trans-, 13-cis-RA, or vehicle to confirm these results.
Similar responses were documented, indicating that the
Figure 1
Analysis of differentially expressed genes in NHEK (a–d) and dermal fibroblasts (e–g) after treatment with 13-cis- and 4-oxo-13-cis-retinoic
acid (RA) for 24 h using the DNA-Chip technology. Total RNA was isolated using peqGOLD RNA Pure. Two micrograms of aRNA from each probe
was labeled by reverse transcription with Cy5 and Cy3 fluorescence, respectively, and subjected to a PIQOR skin microarray. Processing of
microarrays was performed using a fully automated hybridization station. Image capture and signal quantification of hybridized cDNA arrays were
carried out with the ScanArray Lite and ImaGene software version 4.1. Array images and Scatter blot analysis of keratinocytes induced by 10–6 M
13-cis-RA (a, c) and 4-oxo-13-cis-RA (b, d) compared with untreated control. For analysis of gene expression in dermal fibroblast, generation of 33P-
labeled cDNA probe was carried out by reverse transcription of 10 mg total RNA with 33P dCTP for 90 min at 371C following the Mamalian GeneFilters
(Research Genetics) protocol. Purified radiolabeled probe was applied to the array for hybridization at 421C overnight. Afterwards, filters were
exposed to a Kodak X-OMAT AR-5 film at 701C with intensifying screens. Scatter blot analysis of fibroblasts induced by 10–5 M 13-cis-RA (e, f) and
4-oxo-13-cis-RA (e, g) compared with untreated control.
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changes in protein spot intensity reflect changes in protein
concentrations within the NHEK that arise specifically in
these cells as a result of exposure to all-trans- and/or 13-
cis-RA.
For the 26 h study, changes in silver-stained protein spot
intensities reflect changes in protein concentrations within
the NHEK that arise specifically in these cells through ex-
posure to all-trans-RA and/or 13-cis-RA. Consequently, we
excised protein spots from the dried silver-stained gels for
identification of their tryptic fragments by MALDI-MS.
Identities of NHEK proteins whose concentrations
change following all-trans- and 13-cis-RA treat-
ments We were able to identify eight proteins by MALDI-
MS analysis, whose concentrations changed in a similar
manner in response to treatments with all-trans- and 13-cis-
RA. The identities of these eight proteins are shown in Table
S5. For our studies, we concentrated primarily on identifying
proteins that showed relatively large changes in protein
concentration after treatment with RA indicated by an in-
creased/decreased intensity of each silver-stained protein
spots. The proteins can be divided into several groups
based on their physiological roles. Several of the changes in
protein expression such as those for cytokeratins 14, 17, 19
were predicted by our gene array studies and are known to
be RA responsive. Two of the proteins, DNAse I precursor
protein and lamin B1, are localized in the nucleus and are
known to participate in maintaining the structure and or-
ganization of the cellular genome. As far as we are able to
determine, neither DNAse I precursor protein nor Lamin B1
have been previously reported to be RA responsive. One
of the proteins, lecithin:retinol acyltransferase (LRAT), is
thought to be crucial for retinoid homeostasis in the skin
(Kurlandsky et al, 1996). LRAT expression in the liver and
lungs has previously been identified as being RA responsive
(Zolfaghari and Ross, 2000, 2002). Of 11 protein spots ex-
cised from 2D gels for identification, we were unable to
identify three of these following trypsin digestion and MA-
Table I. Differential gene expression in NHEK after incubation with 10–6 M 13-cis-, all-trans-, 9-cis-, 4-oxo-13-cis-, 4-oxo-all-trans-,
or 4-oxo-9-cis-RA for 24 h using the PIQOR Skin microarray (complete data see Table S1)
Gene name 13-cis-RA
4-oxo-13-cis-
RA
All-trans-
RA
4-oxo-all-
trans-RA 9-cis-RA
4-oxo-9-
cis-RA
Interleukin-1b 3.59 2.93 3.87 3.7 3.33 2.81
Tissue-type plasminogen
activator
3.36 3.29 2.1 2.64 3.32 3.19
S100 calcium-binding protein
A8
2.83 1.15 0.67 0.79 0.92 0.87
S100 calcium- binding protein
A9
5.08 2.49 1.17 1.6 1.99 2
S100 calcium-binding protein
A7 (psoriasis)
7.53 1.95 1.73 1.72 1.99 2.2
Cytokeratin 15 3.55 4.09 3.46 3.53 3.58 4.07
Cytokeratin 19 2.15 3.2 2.2 2.14 2.64 2.81
Cytokeratin 7 3.26 3.96 2.57 3.9 4.43 4.54
Interleukin-1 receptor 0.54 0.66 0.4 0.47 0.59 0.45
Vascular endothelial growth
factor c
0.6 0.69 0.62 0.6 0.6 0.69
Plasminogen activator inhibitor-
2
0.77 0.67 0.7 0.63 0.69 0.57
Stromelysin-2 (matrix
metalloproteinase-10)
0.53 0.64 0.4 0.37 0.39 0.47
Thrombospondin1 0.85 0.78 0.94 0.88 0.57 0.69
Fatty acid-binding protein,
epidermal (psoriasis-associated
fatty acid-binding protein
homolog)
0.41 0.63 0.45 0.48 0.64 0.58
Cyclooxygenase-2 0.18 0.21 0.19 0.17 0.17 0.15
Cytokeratin 1 0.54 0.48 0.33 0.35 0.33 0.49
Cytokeratin 10 0.47 0.37 0.29 0.3 0.39 0.31
Cytokeratin 14 0.56 0.78 0.55 0.68 0.66 0.83
Cytokeratin 17 0.55 0.72 0.43 0.6 0.6 0.61
Filaggrin (profilaggrin) 0.88 0.39 0.3 0.28 0.28 0.27
NHEK, normal human epidermal keratinocytes; RA, retinoic acid.
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LDI-MS analysis. Two of the spots contained insufficient
protein to provide an identifiable fragmentation pattern. The
third consisted of a mixture of proteins for which unequiv-
ocal identification was not possible.
Discussion
Retinoids are among the most effective categories of ther-
apeutic agents used in the treatment of dermatological dis-
orders. Although extensive studies have been conducted to
define the pharmacological action of the retinoids in the
skin, their mechanism of action remains ill defined. Using
cDNA-Chip technology, we showed that RA and their 4-
oxo-metabolites have differential effects on gene expres-
sion in NHEK and fibroblasts (Fig 1, Table I, and Tables S1–
S3). Interestingly, all of the 4-oxo-RA metabolites showed
transcriptional regulatory activity including 4-oxo-13-cis-
RA, which has generally been thought to be an inactive
metabolite of 13-cis-RA (Figs 1–3, Table I, and Tables S1–
S3). Each of the 4-oxo-metabolites showed similar expres-
sion profiles but significantly different effects on gene reg-
ulation (Figs 1–3, Table S1, Tables S1–S4).
Our gene array data confirm and extend earlier work on
the effects of RA on gene expression in the skin, especially
regarding cytokeratin gene expression. It is known that
cytokeratin 10 is a marker for epidermal hyperproliferation
and differentiation (Mommers et al, 2000) and its expression
is known to be upregulated in psoriasis (Mommers et al,
2000) and downregulated in NHEK (Poumay et al, 1999).
Similarly, cytokeratin 13 is thought to be a marker of em-
bryonic differentiation and upregulation of cytokeratin 13 by
all-trans-RA and tazarotene has been shown by van Ros-
sum et al (2000) and Virtanen et al (2000). Our data con-
firmed that the RA isomers and their 4-oxo-metabolites
analyzed in this study exert similar effects on the expression
of cytokeratins 10 and 13 in NHEK (Fig 1, Table I, Tables S1
and S4). We showed, at both the mRNA and protein levels,
that treatment of NHEK with each of the different RA iso-
mers and their 4-oxo-metabolites downregulates mRNA
Figure 2
Confirmation of cDNA microarray and 2D-gel electrophoresis data using real-time PCR. (a–f) TaqMan real-time PCR analyses: normal human
epidermal keratinocytes (NHEK) were stimulated with different RA isomers and metabolites at a concentration of 10–6 M for 24 h. Total RNA was
isolated and untreated NHEK were used as control. The relative keratin 1, 10, 13, 19, matrix metalloproteinase-3, and lamin B1 RNA levels were
normalized to 18S RNA.
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expression of keratin 14, a known basal cell layer keratin in
stratified squamous epithelium (Green et al, 2003). In ad-
dition, our gene array data showed upregulation of mRNA
for keratins 7 and 19 that was confirmed by immunoflu-
oresence studies of NHEK treated with the different re-
tinoids (Fig 3, Table I, and Table S1).
It is well established that MMP are important for con-
nective tissue structure and function. Furthermore, it has
been suggested that some of the beneficial actions of re-
tinoids relate to effects on MMP gene expression. Our re-
sults showed that RA treatment downregulated both MMP-
3 (stromelysin-1, Fig 3) and MMP-10 (stromelysin-2, Table I,
Figure 3
Confirmation of cDNA microarray and 2D gel
electrophoresis data using immunofluores-
cence. For immunofluorescent examination, nor-
mal human epidermal keratinocytes were
seeded into chamber slides and induced with
10–6 M 13-cis-, all-trans-, 9-cis-, 4-oxo-13-cis-,
4-oxo-all-trans-, or 4-oxo-9-cis-RA for 24 h. The
chamber slides were then incubated with spe-
cific primary antibodies against cytokeratin 7
(CK7) or cytokeratin 19 (CK19) for 60 min and
subsequently with a secondary FITC-conjugated
rabbit anti-mouse antibody for 30 min.
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and Table S1) in NHEK. Overexpression of MMP-3 is asso-
ciated with poor wound healing (Fray et al, 2003). Moreover,
MMP-3 is overexpressed in murine skin tumors and is as-
sociated with a metastatic cell phenotype (Leite-Browning
et al, 2002). Increased expression of MMP-3 has also been
found in human malignant melanoma, especially in the ex-
tracellular matrix adjacent to blood vessels (Bodey et al,
2001). We propose that the downregulatory effect of each of
the retinoids on MMP-3 expression could explain some of
the known anti-carcinogenic properties of the retinoids. A
similar downregulatory effect on the expression of other
MMP was described in vivo and in vitro after administration
of all-trans-RA. Levels of latent and active MMP-9 and
MMP-13 were reduced by 50%–75% (po0.05) by all-trans-
RA in organ cultures of skin from streptozotocin-diabetic
rats, and Fisher et al (1999) showed that pretreatment of
human skin with all-trans-RA inhibits UV induction of MMP,
suggesting that this retinoid can reverse UV-induced dam-
age to connective tissue and may be able to limit or improve
photoaging changes in the skin. MMP-10 (stromelysin-2) is
expressed in keratinocytes growing at the edge of healing
skin wounds. Krampert et al (2004) showed that precise
regulation of stromelysin-2 is required for limited matrix
degradation at the wound site, thereby controlling keratin-
ocyte migration. This correlates with our findings, revealing
a strong downregulatory effect of all analyzed retinoids on
expression of MMP-10.
In human epidermis, basal keratinocytes are the main
source of IL-1, and IL-1a is the predominant isoform,
whereas IL-1b appears to be expressed predominantly in
cultured keratinocytes. Radioimmunoassay performed by
Gatto et al (1993) showed that after stimulation by all-trans-
RA, intracellular IL-1b is predominantly increased, with no
significant modification of IL-1a expression. This is consist-
ent with our findings, revealing a significant upregulation of
IL-1b after stimulation with RA isomers and their 4-oxo-
metabolites both after 3 and 24 h of incubation (Table I,
Tables S1 and S2).
VEGF is overexpressed in hyperproliferative diseases,
such as psoriasis and cancers, in which there is increased
angiogenesis. Using normal human keratinocytes in con-
ventional cultures and skin grafted onto nude mice in vivo,
Diaz et al (2000) showed that retinoids can inhibit TPA-me-
diated VEGF gene induction at the transcriptional level. We
obtained similar results in array experiments after incuba-
tion with 10–6 M 13-cis-, all-trans-, 9-cis-, 4-oxo-13-cis-, 4-
oxo-all-trans-, or 4-oxo-9-cis-RA for 3 and 24 h.
Axel et al (2001) demonstrated downregulation of mRNA
expression of the glycoprotein thrombospondin-1 in human
arterial smooth muscle cells after all-trans-RA treatment.
Similar findings were detected in our in vitro studies using
NHEK (Table I, Tables S1 and S2).
The activation of the proteolytic plasminogen activator
system is important for the re-epithelialization of skin
wounds. Keratinocytes synthesize and secrete the uroki-
nase-type plasminogen activator, which binds to its specific
keratinocyte surface receptor. Receptor-bound urokinase-
type plasminogen activator efficiently activates cell surface-
bound plasminogen. Braungart et al (2001) showed that all-
trans RA augments urokinase-type plasminogen activator.
Our studies revealed similar effects, showing an upregula-
tion of tissue-type plasminogen activator, especially after
stimulation of NHEK with 13-cis- or 4-oxo-13-cis-RA and a
downregulation of plasminogen activator inhibitor-2 by all
RA analyzed. This activation of the plasminogen activator
system may be one mechanism whereby all-trans-RA ex-
erts beneficial effects in cutaneous wound healing.
PA-FABP is a new member of a group of low-molecular-
weight proteins that are strongly upregulated in psoriatic
skin and that share a similarity with fatty acid-binding pro-
teins (Madsen et al, 1992). Ha et al (2004) recently showed
that expression of PA-FABP was elevated in senescent hu-
man dermal microvascular endothelial cells, suggesting that
overexpression of FABP in cultured senescent human der-
mal microvascular endothelial cells is closely related to skin
aging. Our cDNA microarray in vitro study (Table I, Table S1)
revealed a 2-fold downregulation of PA-FABP, suggesting
that retinoids can alter the fatty acid metabolism in human
skin cells.
Kanekura et al (2000) showed that the constitutive ex-
pressions of cyclooxygenase (COX)-2 protein and pros-
taglandin E(2) (PGE(2)) biosynthesis were significantly
enhanced in human skin epidermal cancer cells and that
cancer cell growth was effectively inhibited by the suppres-
sion of COX-2 expression by transfection with COX-2 an-
tisense oligonucleotide. Retinoids and antioxidants have
been used for the chemoprevention of cancers in several
tissues and treatment with 9-cis-RA suppressed COX-2 ex-
pression and PGE(2) biosynthesis and cell growth in human
skin squamous carcinoma cells. We have shown a 5-fold
downregulation of COX-2 by all RA isomers and 4-oxo-
metabolites analyzed (Table I, Table S1). These results fur-
ther support the hypothesis that retinoids play a role in
preventing skin cancer growth by influencing the expression
of COX-2.
Filaggrin is a basic protein normally present in the stra-
tum corneum. It derives from profillagrin, a high-molecular-
weight precursor synthesized in the stratum granulosum
that is thought to be associated with the keratohyaline
granules of granular cells. Asselineau et al (1990) showed
that the accumulation of filaggrin in the outermost layers of
submerged cultured human keratinocytes is enhanced after
removing retinoids from the serum supplement and subse-
quently inhibited when small concentrations of RA are re-
added to the culture medium. This correlates with our cDNA
array data revealing downregulaton of filaggrin after incu-
bation with RA isomers and especially their 4-oxo-met-
abolites (Table I, Table S1).
Each of the RA isomers and their 4-oxo-metabolites al-
tered gene expression in skin ﬁbroblasts (Table S3). The
retinoids downregulated several CYP isoenzymes and
transporter proteins such as the monocarboxylate trans-
porter 1 (SLC16A1), which is responsible for the cellular
uptake of monocarboxylic acids, i.e., lactate, pyruvate, and
ketone bodies. (Garcia et al, 1994; Koehler-Stec et al, 1998;
Daberkow et al, 2003). Regulation of the expression of these
transporters by RA (Table S3) has not been described pre-
viously. Similarly, retinoid treatment downregulated the ex-
pression of collagen types VI and XVII in fibroblasts. Ogawa
et al (1998) showed that increasing concentrations of all-
trans-RA decrease cell proliferation and synthesis of
collagen in human dermal fibroblasts. This observation
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correlates well with our data and taken together, these
findings suggest that retinoids could have therapeutic ef-
fects in hypertrophic scars and keloids (Daly and Weston,
1986; Ogawa et al, 1998). We also observed upregulation of
genes encoding annexin I and V in fibroblasts by all-trans-
and 13-cis-RA (Table S3). RA treatment of growth plate
chondrocytes is reported to cause an increase in cytosolic
calcium concentration, followed by upregulation of annexin
gene expression, including annexins II, V, and VI gene ex-
pression (Wang et al, 2003). Possibly, a similar mechanism
is involved in the upregulation of annexins I and V in dermal
fibroblasts.
Through MALDI-MS analysis of 2D gels, we showed that
the retinoids altered the expression of 8 proteins in NHEK.
Three of these were cytokeratins (14, 17, and 19) for which
changes in mRNA levels could account for an increase/de-
crease in cellular protein level. In the case of lamin B1, we
were unable to detect changes in NHEK levels of mRNA
encoding the protein (Fig 3f). LRAT mRNA and activity levels
in rodent liver and lungs are reported to be responsive to RA
(Zolfaghari and Ross, 2000, 2002). LRAT has been pro-
posed to be important in keratinocytes for maintaining re-
tinoid availability to allow for the continued synthesis of RA
in the cells (Kurlandsky et al, 1996; Zolfaghari and Ross,
2000, 2002). It is thought that, when RA levels are sufficient
to meet cellular needs, LRAT level/activity is upregulated to
allow for additional retinoid storage. Our finding that LRAT
protein levels are upregulated in RA-treated NHEK is con-
sistent with this notion. This is a report of an increase in
LRAT protein levels in RA-treated cells that is not accom-
panied by a change in LRAT mRNA levels as assessed by
Northern blot analysis. Our data do not provide an expla-
nation for this observation aside from suggesting that either
the rate(s) of LRAT protein synthesis and/or degradation
must be altered in NHEK treated with RA.
Lamin B1 proteins levels but not mRNA levels, were also
elevated in RA-treated NHEK and this may be especially
interesting for understanding all-trans- and 13-cis-RA ac-
tions within NHEK, suggesting for the first time that this
protein is retinoid responsive. Lamin B1 is a major compo-
nent of the nuclear lamina, a proteinaceous layer found at
the interface between chromatin and the inner nuclear
membrane, and it is thought to interact with the basal tran-
scription machinery and to provide a scaffold for the as-
sembly or stabilization of active transcription complexes
(Goldman et al, 2002; Holaska et al, 2002; Shumaker et al,
2003). Lamin assembly is proposed to be involved in trig-
gering apoptosis and is important for nuclear envelope for-
mation and integrity. Although lamin B1 is not currently
known to play a role in the development of skin disease, it is
widely expressed in cells found in the skin (Broers et al,
1997; Tilli et al, 2003). Should the changes that we observed
in lamin B1 protein concentrations in NHEK not involve
transcriptional mechanisms, this might be very important for
understanding non-genomic actions of all-trans- and/or 13-
cis-RA within skin cells.
In summary, we have identified substantial metabolic
differences between NHEK and human dermal fibroblasts in
the processing of RA and their 4-oxo-metabolites. These
differences may help to explain the differential therapeutic
efficacy of RA isomers and their metabolites. We demon-
strated that the 4-oxo-RA metabolites have transcriptional
activity in skin cells and that the various isomers have dis-
tinct transactivational profiles that are specific to NHEK and
dermal fibroblasts. In addition, we have identified several
novel gene products, either as mRNA species or proteins
that are present in NHEK or fibroblasts and that were not
previously known to be RA responsive. Further studies are
needed to clarify the mechanism whereby these very dis-
tinct actions are coordinately regulated and controlled in
maintaining skin homeostasis.
Material and Methods
Cell culture NHEK were obtained from healthy male donors un-
dergoing circumcision. All studies were approved by the ethical
committee of the University Hospital, RWTH, Aachen. Participants
gave their written informed consent, and the study was conducted
according to the Declaration of Helsinki Principles. Skin specimens
were rinsed three times in sterile phosphate-buffered saline (PBS)
(PAA, Linz, Austria), containing antibiotics (penicillin/streptomycin,
PAA), and amphothericin B (PAA) and cut into 2  2 mm small
pieces. These were placed in 2 U per mL dispase solution (Gib-
coBRL, Paisley, Scotland, UK) overnight at 41C and additionally
incubated at 371C for 30 min. The epidermis was peeled from the
dermis and incubated in trypsin/EDTA (Cambrex, Walkersville,
Maryland) for 30 min at 371C. The enzymatic digestion was
stopped by Trypsin Neutralization Solution (Cambrex). The stratum
corneum was removed by filtering the digest through a 40 mm
nylon strainer (Falcon, Franklin Lakes, New Jersey). The resulting
cell suspension was centrifuged for 6 min at 500  g (Heraeus
Labofuge 400, Hanau, Germany), and the cell pellet was resus-
pended in fully supplemented keratinocyte growth medium (KGM,
Cambrex, 0.015 mM calcium). The cells were cultured in a humid-
ified atmosphere at 5% CO2 (MCBI incubator, Sanyo, Japan). Cells
used in our studies were always from the first and second passage
and in a state of late subconfluency.
Keratinocytes used in the 2D experiment were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (high glucose)/
Ham’s F12 (3:1) Medium (GibcoBRL) supplemented with 10% fe-
tal calf serum (FCS) (Biochrom AG, Berlin, Germany), antibiotics
(penicillin/streptomycin, PAA), amphothericin B (PAA), adenine
(0.18 mM) (Sigma Chemical, St Louis, Missouri), cholera toxin
(100 pM) (Sigma), epidermal growth factor (10 ng per mL) (Roche,
Mannheim, Germany), FCS (10%) (Biochrom), hydrocortisone
(0.4 mg per mL) (Serva, Heidelberg, Germany), insulin (5 mg per
mL) (Roche), non-essential amino acids (PAA), transferrin (5 mg per
mL) (Promo Cell, Heidelberg, Germany), and triiodothyronine (2 nM)
(Sigma).
Normal human fibroblasts were obtained from discarded fore-
skin specimens. After the removal of the epidermis, the dermis was
placed in a dry cell culture multi-well plate (Falcon) for 20 min, to
allow adherence to the polystyrene surface of the culture plate.
DMEM (high glucose and containing L-glutamine; GibcoBRL) sup-
plemented with 10% FCS (Biochrom), antibiotics (penicillin/strep-
tomycin, PAA), and amphothericin B (PAA) was added. Fibroblast
outgrowth was monitored by light microscopy (LEICA DMIL; Leitz,
Wetzlar, Germany), and dermal remnants were removed after 5–7
days. On reaching late subconfluency, cells were subcultivated
using the same media. Cells used in our experiments were from
low passages (po5) and in a state of late subconfluency.
Retinoid treatment of the cells Under dim red light, we added
either RA isomers or their 4-oxo-metabolites (kindly provided by Dr
Ulf Wiegand, F. Hoffman La-Roche, Basel, Switzerland) freshly
prepared as stocks in dimethyl sulfoxide (Merck, Darmstadt, Ger-
many) to NHEK or dermal fibroblasts in culture. In all these exper-
iments, the final concentration of the solvent added to the culture
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medium was less than 0.1% of the culture medium. Treated cells
were incubated for 24 or 72 h at 5% CO2 and 371C in a humidified
atmosphere in the dark. Prior to expression studies, high-perform-
ance liquid chromatography analyses of treated NHEK and fibro-
blasts were conducted to verify the stability of RA isomers and
their 4-oxo-metabolites in the presence of these cell types (data
not shown).
Microarray analysis (radiolabeled probes) Total RNA isolated
from dermal fibroblasts that had been incubated with the different
RA isomers and their 4-oxo-metabolites was isolated using peq-
GOLD RNA-Pure (peqlab, Biotechnologie GmbH, Erlangen, Ger-
many) according to protocols provided by the manufacturer.
Generation of 33P-labeled cDNA probes was performed by re-
verse transcription of 10 mg total RNA with 33P dCTP for 90 min at
371C following the Mammalian GeneFilters (Research, Genetics,
Invitrogen, Karlsruhe Germany or Carlsbad, California) protocol. To
remove unincorporated nucleotides, the probes were passed
through Bio-Spin 6 chromatography columns (Bio-Rad Labora-
tories GmbH, Mu¨nchen, Germany). Purified radiolabeled probes
were applied to DermArray GeneFilters microarrays and allowed to
hybridize at 421C overnight. After hybridization, the filters were
washed twice with 2  SSC, 0.1% SDS at 501C for 1 h and once
with 0.5  SSC, 0.1% SDS for 30 min at 551C. Afterwards, filters
were exposed to a Kodak X-OMAT AR-5 film at 701C in cassettes
containing intensifying screens. We analyzed suitably exposed au-
toradiograms using Pathway analysis software (Research Genet-
ics).
Microarray analysis (ﬂuorescent probes) Linear amplification of
total RNA, labeling, and hybridization were performed according to
the manufacturer’s directions (Eberwine, 1996; Bosio et al, 2002).
Amplified RNA (aRNA) samples were quantified by spectropho-
tometry, and the quality was verified by capillary electrophoresis
(Bioanalyser 2001, Agilent Technologies GmbH, Boblingen, Ger-
many). Two micrograms of aRNA from each probe was labeled by
reverse transcription with Cy5 and Cy3 fluorescent nucleotides,
respectively, and subjected to a PIQOR Skin Microarray. Process-
ing of microarrays was performed using a fully automated hybrid-
ization station according to the manufacturer’s guidelines (a-Hyb,
Memorec, Cologne, Germany). Image capture and signal quanti-
fication of hybridized PIQOR cDNA arrays were carried out with the
ScanArray Lite (Perkin Elmer, Life and Analytic Sciences, Boston,
Massachusetts) and ImaGene software version 4.1 (BioDiscovery,
Los Angeles, California).
Quantitative real-time PCR Total RNA from NHEK was isolated
using the High Pure RNA Isolation kit (Roche) according to the
manufacturer’s instructions with inclusion of the DNase step. Pu-
rified RNA was reverse transcribed with the TaqMan Reverse Tran-
scription Reagents kit (Applied Biosystems, Weiterstadt, Germany)
with random hexamers as primers. TaqMan experiments were car-
ried out on an ABI PRISM 7000 Sequence Detection System (Ap-
plied Biosystems) using ‘‘Assay on demand’’ primer/probe sets for
human keratins 1, 10, 13, and 19, MMP-3, and lamin B1 (Applied
Biosystems). A pre-developed TaqMan Assay Reagent for human
18S-RNA (Applied Biosystems) was chosen as an endogenous
control for normalization of the RNA load.
Quantiﬁcation of target gene expression The standard curve
method was used for quantification of gene expression (Applied
Biosystems, User Bulletin 2). Briefly, a cDNA sample of unstimu-
lated NHEK was 2-fold serial diluted to construct standard curves
for human keratins 1, 10, 13, and 19, MMP-3, and lamin B1, and
18S RNA. The keratins, MMP-3, and lamin B1 messages in un-
known samples were quantified, using the standard curves, to de-
termine a relative measure of the starting amount. Each sample
was then normalized on the basis of 18S RNA expression. Finally,
the normalized amount of the target gene is divided by the target
gene quantity of the calibrator, with the calibrator being the un-
stimulated control of NHEK. Thus, results are referred to as tran-
scription relative to the calibrator.
2PAGE Pelleted NHEK treated either with ethanol (vehicle), 2 mM
all-trans-, or 2 mM 13-cis-RA were homogenized in buffer contain-
ing protease inhibitors and treated with nuclease to digest DNA.
Cellular protein content was determined by the Coomassie dye-
binding assay (Bio-Rad), and 50 mg total protein was loaded onto
an isoelectric focusing gel 2.0 mm inner diameter using 2% pH
range 3.5–10.0 ampholines (Amersham Pharmacia Biotech, Pi-
scataway, New Jersey). Isoelectric focusing was carried out for
20,000 Volt-h. Following isoelectric focusing, the proteins were
separated in the second dimension by SDS-PAGE on 10% gels.
The 2D electrophoresis separations were carried out according to
the method of O’Farrell (1975). SDS slab gel electrophoresis was
carried out for 4 h at 12.5 mA per gel. As molecular weight stand-
ards, we used myosin (220,000), phosphorylase A (94,000), cat-
alase (60,000), actin (43,000), carbonic anhydrase (29,000), and
lysozyme (14,000) (Sigma Chemical). After electrophoresis, each
2D electrophoresis gel was silver stained (Bio-Rad) and scanned
by a laser densitometer (Molecular Dynamics, Sunnyvale, Califor-
nia). Patterns of silver-stained proteins were analyzed by Progen-
esis software (Nonlinear Technology, Madison, Wisconsin), such
that all major protein spots and all changing protein spots were
outlined, quantified, and matched for each duplicate gel for each of
the three treatments. For each silver-stained 2D PAGE gel, the
intensity of each spot was calculated as a spot percentage that
equals the integrated density expressed as a percentage of the
total density summed for all protein spots identified.
Identiﬁcation of NHEK proteins by MALDI-MS The identities of
NHEK proteins present as silver-stained spots on the 2D PAGE
gels were determined through MALDI-MS analyses carried out by
the Protein Chemistry Core Facility of the Howard Hughes Medical
Institute at Columbia University. For this purpose, silver-stained
protein spots were carefully dissected from the dried 2D PAGE gels
using a sharp pointed scalpel. The excised gel fragment was
treated with trypsin to digest proteins in situ. The resulting tryptic
fragments were then subjected to MALDI-MS analysis, and the
identities of proteins present in the spots were determined through
search of the NCBI GenBank database. Detailed protocols for
these procedures are available online (http://cpmcnet.columbia.
edu/dept/protein).
Immunoﬂuorescence For immunofluorescence examination of
monolayers, cells were seeded into chamber slides (4-well Lab-Tek
II, Nunc (GmbH and Co.) Wiesbaden, Germany). NHEK were fixed
in ice-cold methanol for 10 min, rinsed in PBS, and washed in tris-
buffered saline (TBS) (DAKO, Carpinteria, California) for 10 min.
The chamber slides were incubated with primary monoclonal an-
tibodies (anti-human cytokeratin 7 (Novocastra, Newcastle upon
Tyne, UK) diluted 1:50 or anti-human cytokeratin 19 (Research Di-
agnostics, Flanders, New Jersey) diluted 1:10). For each specific
antibody or the isotypic control (Sigma), incubations were for 60
min. Slides were washed three times for 10 min each with TBS.
Subsequently, cells were incubated for 30 min with a secondary
FITC-conjugated rabbit anti-mouse antibody (DAKO), washed two
times for 10 min with TBS, and mounted with Immu-Mount (Shan-
don, Pittsburgh, Pennsylvania).
These studies were supported by grants R01 DK052444 and R01
DK061310 from the National Institutes of Health.
Supplementary Material
The following material is available from http://www.blackwellpublish-
ing.com/products/journals/suppmat/JID/JID23791/JID23791.htm
Figure S1 Two-dimensional (2D) gel electrophoresis of total cellular
proteins from NHEKs treated for 26 h with 2 mM 13-cis-RA.
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Table S1 Differential gene expression in NHEKs after incubation with
106 M 13-cis-RA, all-trans-RA, 9-cis-RA, 4-oxo-13-cis-RA, 4-oxo-all-
trans-RA or 4-oxo-9-cis-RA for 24 hours using the PIQOR Skin
microarray.
Table S2 Differential gene expression in NHEKs after incubation with
106 M 13-cis-RA, all-trans-RA, 9-cis-RA, 4-oxo-13-cis-RA, 4-oxo-all-
trans-RA or 4-oxo-9-cis-RA for 3 hours using the PIQOR Skin
microarray.
Table S3 Differential gene expression in dermal ﬁbroblasts after
incubation with the RA-isomers and 4-oxo metabolites for 24 hours
using the DermArray GeneFilters microarray (¼ not regulated).
Table S4 TaqMan real-time PCR analyses of NHEKs stimulated with
different RA isomers and metabolites at concentrations of 107and 108
M for 24 hours.
Table S5 Human keratinocyte proteins identiﬁed by MALDI-MS whose
levels change upon treatment with all-trans-retinoic acid or 13-cis-
retinoic acid.
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